Background Pembrolizumab improved progression-free survival and overall survival versus
ipilimumab in patients with advanced melanoma and is now a standard of care in the first …

Importance Nivolumab, a monoclonal antibody that inhibits programmed cell death 1, is
approved by the US Food and Drug Administration for treating advanced melanoma, renal …

Abstract PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has
revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 …

There has been significant progress in the treatment of patients with advanced clear cell
renal cell carcinoma (ccRCC), with improved knowledge of disease biology and the …

Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …

Melanoma is among the most sensitive of malignancies to immune modulation. Although
multiple trials conducted over decades with vaccines, cytokines, and cell therapies …

Background Programmed cell death protein 1 (PD-1) blocking monoclonal antibodies
improve the overall survival of patients with advanced melanoma but the optimal duration of …

Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …

Highlights•A melanoma consensus conference, organised by the ESMO Guidelines
Committee, was attended by 32 experts from 14 countries•The experts compiled …

Background Patients with advanced melanoma have limited treatment options after
progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor …